Ridgeback Biotherapeutics LP announces licensing of mAb114, an experimental Ebola treatment, from the National Institute of Allergy and Infectious Diseases - Markets Insider

Ridgeback Biotherapeutics LP announces licensing of mAb114, an experimental Ebola treatment, from the National Institute of Allergy and Infectious Diseases  Markets InsiderMIAMI, Dec. 13, 2018 /PRNewswire/ -- Ridgeback Biotherapeutics LP, a closely held biotechnology company, today announced that it has entered into a patent l ...